BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Novartis AG (NVS) Drug Study Data Manipulated: Kyoto Prefectrual University of Medicine


7/12/2013 9:59:01 AM

Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Several months after various scientific papers for the best-selling Diovan heart drug sold by Novartis were retracted and a prominent researcher, who was the principal investigator in most cases, resigned his position from Kyoto Prefectrual University of Medicine, school officials now acknowledge that the underlying data was manipulated. This amounts to an about face - in January, the university conducted a probe and maintained there were no "irregularities." The research was begun in 2004 by Hiroaki Matsubara, a former professor at Kyoto who co-authored papers between 2008 and 2012. These included the Kyoto Heart study, which was published in the European Medical Journal in 2009 and claimed Diovan reduced the risk of heart attacks and strokes, which Novartis (NVS) used in its promotions. The study helped Diovan become a huge seller in Japan and sales reached $5.6 billion worldwide in 2011 before generics became available.

Help employers find you! Check out all the jobs and post your resume.


Read at Pharmalot
Read at Japan Times
Read at News Release
Read at News Release
Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES